Ashlee Rossner
Psychiatric/Mental Health · Springfield, MONPI 1912320862
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 558 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,704, 4.5 times the $600 reported in 2021. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 558 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Supernus Pharmaceuticals, Inc.$976
- Otsuka America Pharmaceutical, Inc.$833
- Alkermes, Inc.$588
- Neurocrine Biosciences, Inc.$554
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$549
- plus $4K from 18 others
What the payments were for
- Food & beverage$8,31798%
- Education$1482%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 105 | $1,416 |
| Supernus Pharmaceuticals, Inc. | 67 | $976 |
| Otsuka America Pharmaceutical, Inc. | 59 | $833 |
| Alkermes, Inc. | 32 | $588 |
| Neurocrine Biosciences, Inc. | 25 | $554 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $549 |
| Indivior Inc. | 27 | $513 |
| Axsome Therapeutics, Inc. | 26 | $489 |
| Teva Pharmaceuticals USA, Inc. | 35 | $420 |
| E.r. Squibb & Sons, L.L.C. | 33 | $374 |
| Corium, LLC | 11 | $269 |
| Johnson & Johnson | 14 | $254 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $205 |
| Lundbeck LLC | 10 | $188 |
| Sunovion Pharmaceuticals Inc. | 13 | $176 |
| Pfizer | 17 | $159 |
| Vanda Pharmaceuticals Inc. | 8 | $139 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $122 |
| Merck | 4 | $61 |
| Collegium Pharmaceutical, Inc. | 3 | $50 |
| Avanir Pharmaceuticals, Inc. | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Ironshore Pharmaceuticals Inc. | 2 | $31 |
| Almatica Pharma LLC | 1 | $20 |
How this compares
$8,465 in reported general payments places this provider in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 219 | $350,563 |
| Invega SustennaPaliperidone Palmitate | 53 | $184,937 |
| Invega TrinzaPaliperidone Palmitate | 14 | $147,737 |
| IngrezzaValbenazine Tosylate | 16 | $145,908 |
| RexultiBrexpiprazole | 70 | $106,759 |
| AustedoDeutetrabenazine | 14 | $88,168 |
| TrintellixVortioxetine Hydrobromide | 150 | $86,394 |
| Abilify MaintenaAripiprazole | 27 | $75,797 |
| MounjaroTirzepatide | 37 | $45,898 |
| LinzessLinaclotide | 74 | $39,951 |
| OzempicSemaglutide | 39 | $35,457 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 182 | $30,453 |
| EliquisApixaban | 50 | $30,160 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $25,321 |
| BelsomraSuvorexant | 54 | $23,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess | $1,416 | $390,514293 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $254 | $332,67467 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $833 | $182,55697 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $554 | $145,90816 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $420 | $88,16814 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $205 | $86,394150 claims |
| PfizerEliquis | $159 | $30,16050 claims |
| Alkermes, Inc.Lybalvi | $588 | $25,32116 claims |
| MerckBelsomra | $61 | $23,15754 claims |
| Axsome Therapeutics, Inc.Auvelity | $489 | $15,85312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Springfield
- Erin DuvallSpringfield$275K
- Emily WoukSpringfield$90K
- Karin BaughmanSpringfield$16K
- Tedra EstisSpringfield$13K
- Brian SmithSpringfield$10K
- Holly JulianSpringfield$6K
- Kendra RasmussenSpringfield$6K
- Aldijana SacicSaint Louis$510K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.